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Abstract 
11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) is an enzyme that activates cortisone into cortisol in tissues. 
Alterations in this enzyme are related to the development of metabolic syndrome, obesity and hyperadrenocorticism 
(HAC). Endothelial nitric oxide synthase (eNOS) produces nitric oxide and is related to the regulation of adrenal 
steroidogenesis. The aim of the study was to evaluate 11β-HSD1 and eNOS expression in dogs with HAC. Visceral 
adipose tissue samples were taken to evaluate 11β-HSD1 expression by immunohistochemistry and western blotting. 
In parallel, adrenal gland samples were collected to evaluate eNOS expression by immunohistochemistry. 11β-HSD1 
expression was significantly higher in the adipocytes of dogs with HAC than in those of the control dogs. eNOS 
expression in the adrenal cortex (zona fasciculata) was significantly lower in the dogs with HAC than in the control 
dogs. 11β-HSD1 overexpression and eNOS underexpression could play a role in the maintenance of hypercortisolism 
in dogs with HAC. 
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Introduction 
The actions of glucocorticoids in target tissues are 
determined by the "nuclear" density of their receptors 
and the intracellular metabolism of the 11β-
hydroxysteroid dehydrogenase (11β-HSD) isoforms 
(Chapman et al., 2013). 11β-HSD is an enzyme that 
interconverts inactive glucocorticoid compounds 
(cortisone) into active compounds (cortisol) and vice 
versa (Seckl and Walker, 2001; Sieber-Ruckstuhl et al., 
2007). Two isoforms of the enzyme have been 
described: 11β-HSD1 mainly catalyses the activation of 
cortisone to cortisol to increase the intracellular cortisol 
levels and thus amplifies its cellular actions (Morton 
and Seckl, 2008), whereas 11β-HSD2 catalyses the 
reverse reaction (Tomlinson et al., 2004). Given the 
physiological relevance of both 11β-HSD isoforms, 
they are referred to as "intracellular gate-keepers of 
tissue glucocorticoid action" (Chapman et al., 2013). 
11β-HSD1 is constitutively expressed in a wide range 
of tissues, including the liver, adipose tissue, pancreatic 
islets, bone, gonads, and the nervous system. 
Additionally, expression of this enzyme can be induced 
in fibroblasts, smooth and skeletal muscle, and cells of 
the immune system (Sieber-Ruckstuhl et al., 2007; 
Ryan et al., 2011; Champan et al., 2013). 
Recently, studies on the expression and actions of the 
11β-HSD1 enzyme have become relevant because 
alterations of the enzyme are associated with metabolic 
syndrome, obesity (Wake and Walker, 2004; Walker 
and Andrews, 2006), and the metabolic complications 
of hyperadrenocorticism (HAC) (Morgan et al., 2016). 
Various studies have reported that 11β-HSD1 
expression is increased in the visceral adipose tissues 
and livers of obese patients (Livingstone et al., 2000; 
Paulmyer-Lacroix et al., 2002; Candia et al., 2012). 
This increase in turn increases the local and/or systemic 
cortisol concentrations, thereby favouring its 
detrimental effects (Seckl and Walker, 2001; Stulnig 
and Waldhausl, 2004). 
The hypercortisolism of HAC induces a state of insulin 
resistance that provokes a tendency towards fasting 
hyperglycemia, hypercholesterolemia, 
hypertriglyceridemia, abdominal obesity, hepatic 
steatosis and diabetes mellitus in the most severe cases 
(Pivonello et al., 2010; Di Dalmazi et al., 2012; Miceli 
et al., 2014, 2017). There is evidence that local 
metabolism of glucocorticoids mediated by the 11β-
HSD1 enzyme plays a central role in the development 
of these complications, which challenges the classical 
view that active glucocorticoids in general circulation 
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represent the most important mode of action of 
glucocorticoids (Morgan et al., 2016). 
Nitric oxide (NO) is a gaseous inorganic free radical 
whose function as an intracellular messenger has been 
widely established in a variety of cell types (Nathan, 
1992). NO is generated by the oxidation of L-arginine 
in a reaction catalysed by NO synthase (NOS) (Palmer 
et al., 1988). NO is involved in numerous biological 
processes, including smooth muscle relaxation, 
neurotransmission, cytotoxicity, and nociception 
(Furchgott and Zawadaki, 1980; Palmer et al., 1987; 
Garthwaite, 1993; Paradise et al. 2010). Three NOS 
isoforms have been identified: neuronal (nNOS), 
endothelial (eNOS), and inducible (iNOS) (Sessa, 
1994). eNOS is located in many tissues mainly on the 
cellular plasma membrane but is also found in the 
cytosol, nucleus, Golgi apparatus, and mitochondria 
(Oess et al., 2006). 
NO is involved in the modulation of various endocrine 
systems (Van Voorhis et al., 1994; Del Punta et al., 
1996; Natarajan et al., 2002). Specifically, in the 
adrenal glands are known to modulate steroidogenesis 
in rat adrenal zona fasciculata cells (Cymeryng et al., 
1998, 2002), in which an inhibitory effect of NO has 
been demonstrated. Although adrenal steroidogenesis 
is regulated primarily by adrenocorticotropic hormone 
(ACTH), the various cell types that compose the 
structure of the cortex and adrenal medulla secrete 
compounds that play roles in the fine-tuning of the 
regulation of adrenal physiology (Hochol et al., 2004; 
Conconi et al., 2006; Bornstein et al., 2008; Ducsay and 
Myers, 2011). 
Cortisol decreases the plasma NO levels by inhibiting 
eNOS (Yang and Zhang, 2004; Liu et al., 2009). In 
dogs with HAC, numerous systemic and metabolic 
disturbances are generated when the vasodilatory effect 
of NO is lost, including hypertension, 
thromboembolism, and blindness (Loscalzo, 1995; 
Mitchell and Webb, 2002; Luchi et al., 2003; Cabrera 
Blatter et al., 2012). 
The objective of the present study was to evaluate 11β-
HSD1 enzyme expression in visceral adipose tissues 
and eNOS expression in the adrenal fascicular cortices 
of dogs with HAC. 
Materials and methods 
Detection of 11β-HSD1 expression in visceral adipose 
tissues 
Study material 
Visceral adipose tissues (n = 16): samples from dogs 
with pituitary-dependent hyperadrenocorticism (PDH) 
(n = 8) were obtained by necropsy from patients with 
PDH who required euthanasia or died for another 
causes (4 females and 4 males; median age of 10 years, 
range 9 to 14 years; 3 Crossbreeds, 2 Poodles, 1 Boxer, 
Labrador Retriever and Dachshund; body condition 
between 7/9 and 8/9, according to Jeusette et al. (2010). 
The diagnosis of PDH was based on history, physical 
examination, routine laboratory findings and an 
increased urine cortisol:creatinine ratio in two 
consecutive morning urine samples collected by the 
owner at home. After collection of the second urine 
sample, three doses of dexamethasone (0.1 mg/kg) 
were administered PO at 8-hour intervals, and a third 
urine sample was collected the following morning, 
according to Kooistra and Galac (2012). The diagnosis 
was further supported by visualisation of the bilateral 
adrenal hyperplasia by ultrasonography and the 
pituitary mass by nuclear magnetic resonance imaging. 
Dogs with an infectious disease (systemic or local), 
pancreatitis, diabetes mellitus, hypothyroidism, 
tumours (except pituitary adenoma) or any other 
systemic disorder capable of inducing insulin 
resistance, or increasing TNF-α, were excluded (Hess, 
2010). Also, dog with abnormalities on complete blood 
count, urinalysis or biochemical profile other than those 
expected with PDH (stress leukogram, low urine 
specific gravity, mild hyperglycemia, dyslipidemia, 
increased alkaline phosphatase or alanine transferase), 
were excluded. In all cases, the common therapy used 
in Argentina was administered, consisting of combined 
treatment with cabergoline (0.07 mg/kg/week, divided 
into doses administered every 48 hours) and 
ketoconazole (15-20 mg/kg administered every 24 
hours) (Castillo et al., 2008; Lien and Huang, 2008). 
All the dogs had a good response to the therapy, 
controlling the clinical signs and regularizing the 
biochemical alterations in less than 3 months. The dogs 
with HAC were euthanized (n = 5) when they were 
seriously compromised with the quality of life of the 
animal, product of the chronic deterioration of the 
disease (median survival time: 26 months, range 18 to 
35 months). 
Samples from control healthy dogs (n = 8) (4 females 
and 4 males; median age of 7 years, range 5 to 11 years; 
4 Crossbreeds, 1 Beagle, Maltese, Yorkshire Terrier; 
body condition between 5/9 and 6/9) were obtained 
during minor surgical procedures (e.g., 
ovariohysterectomy or exploratory laparotomy by 
foreign body; anesthetic protocol (acepromazine-
fentanyl as premedication; propofol as induction, 
insufluorane as maintenance; continuing infusion with 
remifentanyl).  None of these dogs were undergoing 
any treatment with steroids before sampling. 
Immunohistochemical assay 
Visceral adipose tissue samples were fixed in 4% 
buffered formol, embedded in paraffin and processed 
for histological examination. Slices with a 5-µm 
thickness were made from paraffin sections of visceral 
fat. The sections were deparaffinised by passages in 
xylol and decreasing alcohol gradients. The sections 
were washed with PBS (pH 7.6) and permeabilised with 
1x Triton X-100 (Sigma-Aldrich, Saint Louis, USA) in 
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PBS. After washing, peroxidase activity was blocked 
with 3% hydrogen peroxide (H2O2). Further washes 
were performed, and nonspecific binding sites were 
blocked with blocking serum (goat serum in PBS) for 
10 minutes. Then, the samples were washed with PBS. 
The sections were incubated for 2 hours at 37 °C with 
a 1:50 dilution of a rabbit polyclonal antibody against 
amino acid region 65-164 of the 11β-HSD1 enzyme 
(Santa Cruz Biotechnology, H-100, sc-20175) in PBS. 
After two washes, the Immunoperoxidase Detection 
System (Millipore IHC Select) was used. This system 
uses the avidin-biotin-peroxidase (ABC) method. 
Briefly, the sections were incubated for 10 minutes with 
the biotinylated anti-rabbit secondary antibody. After 
another wash, the sections were incubated for 10 
minutes with horseradish peroxidase (HRP)-conjugated 
streptavidin and finally washed with PBS. The reaction 
was developed with the chromogen 3, 3’-
diaminobenzidine (DAB). The sections were stained 
with haematoxylin (as a contrast) for 5 minutes, 
dehydrated (with increasing alcohol gradients and 
xylol), and mounted with Canada balsam. In the 
sections used as negative controls, PBS was included in 
place of the primary antibody. Image analysis: the 
DC180 digital camera and Leica trinocular microscope 
model DMLS were used for image capture. The Qwin 
Plus software from Leica Inc. Corp. was used. Images 
of 30 non-consecutive fields were evaluated in each fat 
slice to determine the intensity of the 11β-HSD1 
immunostaining. To this end, two observers 
(independent from the research project) analysed the 
images, which were scored according to the intensity of 
the staining. The following values were assigned 
(Oberholzer et al., 1996; Ahmad et al., 2011): "0", no 
immunostaining; "1", weak immunolabelling; "2", 
moderate immunolabelling; and "3", strong 
immunostaining. 
Western blotting 
Visceral adipose tissue samples were frozen 
immediately at -80°C until processing (10 months). The 
samples were homogenized in 5 ml of Lysis Buffer (10 
mM Tris-HCl [pH 8], 1% Triton X-100, and 0.5 mM 
acetic acid) with a cocktail of protease inhibitors (25 
mM HEPES, 250 mM sucrose, 4 mM EDTA, 1 µM 
leupeptin, 1 µM aprotinin, and 1 µM pepstatin, pH 7.4). 
The homogenates were centrifuged at 12,000 x g for 10 
minutes at 4 °C. The supernatant was collected, and the 
protein concentrations were quantified using the 
Bradford method (Bio-Rad Laboratories) (Sapan et al., 
1999). Equal amounts of protein per sample (30-40 g) 
were boiled for 5 minutes in Lysis Buffer (0.06 M Tris-
HCl [pH 6.8], 25% v/v glycerol, 2% w/v SDS, 0.01% 
w/v bromophenol blue, and 5% v/v β-
mercaptoethanol). Then, the proteins were subjected to 
polyacrylamide gel electrophoresis under denaturing 
conditions (SDS-PAGE) and transferred to a 
nitrocellulose membrane (Bio-Rad Laboratories). The 
membranes were blocked with 5% skim milk in 0.1% 
PBS-Tween (PBS-T) and incubated overnight (16 
hours at 4 °C, constant agitation) with a rabbit 
polyclonal antibody against the 65-164 amino acid 
region of the 11β-HSD1 enzyme (Santa Cruz 
Biotechnology, H-100, sc-20175;1:200 dilution) and 
the G9545 rabbit anti-GAPDH antibody (1:100,000 
dilution). After three washes (10 minutes at room 
temperature) in PBS-T, the membranes were incubated 
for 2 hours with the HRP-conjugated anti-rabbit IgG 
secondary antibody (1:4000 dilution). Finally, the 
reaction was developed by incubating the membrane 
for 1 minute in a peroxidase substrate solution for 
enhanced chemiluminescence (ECL). The bands were 
digitized using the GBOX and measured with the 
ImageJ software (NIH, Bethesda, MD, USA). The 
results are normalized to the expression of a 
constitutive protein (GAPDH). 
Detection of eNOS expression in the adrenal cortex 
Study material 
Adrenal glands (n = 18): samples from dogs with HAC 
(n = 8) were obtained by necropsy of patients with PDH 
(the same dogs previously mentioned), whereas control 
samples (n = 10) (5 females and 5 males; median age of 
9 years, range 6 to 14 years; 5 Crossbreeds, 1 Golden 
Retriever, Beagle, Poodle, Pit Bull Terrier, Jack 
Russell; body condition between 5/9 and 7/9) were 
obtained by necropsy of animals euthanized for 
humanitarian reasons and by veterinary indication 
(medullary compression and polytrauma). These dogs 
were euthanized because they arrived at the hospital 
with a severe trauma, from which there was no 
possibility of recovery (traffic accident or fall height). 
Immunohistochemistry assay 
The same immunohistochemistry protocol described 
above was used. The sections were incubated for 2 
hours at 37 °C with a 1:250 dilution of a rabbit 
polyclonal antibody against eNOS (Thermo Fisher 
Scientific, PA3-031A) in PBS. Image analysis: Images 
of 50 non-consecutive fields were evaluated in each 
adrenal cortex to determine the optical density of the 
cortex (zona fasciculata). The optical intensity analysis 
was performed after transforming the images to 
greyscale (8-bit). Calibration for the optical density was 
performed using a calibrated scale tablet ("step tablet"). 
The calibration curve ranged from 0 to 2.6 (optical 
density units) according to Oberholzer et al. (1996). 
Thus, the optical density value increased as the staining 
strength increased. 
Statistical analysis 
Prior to analysing the normality of the variables 
(D’Agostino-Pearson omnibus normality test), the 
experimental results were analysed using a t test (for 
unpaired samples, significant at P<0.05) and expressed 
as the mean ± SEM. To analyse 11β-HSD1 protein 
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expression based on the western blotting results, one-
way ANOVA and Tukey's test were performed (Graph 
Pad Prism 6, USA-California).  
Ethical approval 
The Ethics Committee of the Faculty of Veterinary 
Science (CICUAL) and the Office of Science at the 
University of Buenos Aires approved the present study 
according to the laws on experimentation in animals in 
Argentina and World Health Organization 
recommendations. Signed consent was obtained from 
the dogs’ owners for participation in the present project. 
Results 
Visceral adipose tissue from dogs with HAC clearly 
express11β-HSD1 enzyme more than normal weighted 
dog (Fig. 1).  Expression average score of the 11β-
HSD1 enzyme was significantly higher (P=0.02) in the 
adipocytes of the visceral adipose tissues from the HAC 
dogs than in those from the control dogs based on the 
immunohistochemistry analysis  (Control: 1.125 ± 
0.227; HAC: 2 ± 0.267). Likewise, 11β-HSD1 enzyme 
expression (Fig.2) in the adipocytes was significantly 
higher in the visceral adipose tissues from the dogs with 
HAC than in those from the control dogs based on the 
optical density and western blotting analysis (P=0.041).  
With respect to the eNOS enzyme (Fig.3), 
immunostaining of the adrenal cells from fasciculata 
zone showed more expression (antigen concentration) 
in control dogs than in HAC dogs. The optical density 
was significantly higher in the control dogs than in the 
HAC dogs (P=0.008) (Control: 0.824 ± 0.047; HAC: 
0.661 ± 0.039). 
Discussion 
In the study on visceral adipose tissue, we observed that 
11β-HSD1 was expressed at higher levels in the 
adipocytes of dogs with HAC than in those of the 
control dogs. These results agree with those reported by 
Ahmad et al. (2011), who showed that the visceral 
adipose tissues of rats treated with dexamethasone had 
hypertrophy, hyperplasia and greater 11β-HSD1 
expression than control rats. Similarly, Morgan et al. 
(2014) demonstrated that glucocorticoid-treated mice 
not only had greater 11β-HSD1 expression in their 
adipose and hepatic tissues than control mice but also 
exhibited increased enzyme activity. 
The role of 11β-HSD1 in the development of HAC was 
first described by Tomlinson et al. (2002), who 
reported an extremely rare case of a PDH patient with 
no Cushing phenotype (no hypertension, no muscle 
atrophy, and no fat redistribution). These authors 
demonstrated that the patient had a functional defect in 
the 11β-HSD1 enzyme that rendered it inactive, which 
correspondingly decreased the conversion of cortisone 
to cortisol at the local level. Later, the same enzymatic 
defect and the same clinical picture were described in a 
patient with HAC resulting from an adrenocortical non-
hypophyseal tumour (Arai et al., 2008).  
 
Fig. 1. Immunostaining for 11β-HSD1 (A) and Average score 
of 11β-HSD1 expression (B) in dog visceral adipose tissue. 
(A): Negative control (a), healthy normal-weight dogs (b), 
dogs with HAC (c). Brown cytoplasm indicates positive 
labelling, whereas blue cytoplasm and nuclei are negative 
(haematoxylin). Arrows indicate areas with stronger staining. 
The scale bar is 100 μm. (B): Average score from HAC dogs 
are significantly higher (* P=0.02) than in control dogs. 
Values expressed as the mean ± SEM. 
 
 
Fig. 2. 11β-HSD1 expression in visceral adipose tissues 
determined optical density and  western blotting in the control 
dogs and dogs with HAC. The enzyme are highly expressed 
in HAC (*P<0.05) according to the optical density analyse 
(top figure) and western blott (bottom figure). Values are 
expressed as the mean ± SEM. 
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Fig. 3. Immunostaining (A) for eNOS in the adrenal cortex 
(zona fasciculata) and Optical density (B) of the adrenal cells 
(zona fasciculata). (A): Negative control (a), healthy normal-
weight dogs (b), dogs with HAC (c). Brown cytoplasm and 
nuclei indicate positive staining, whereas blue cytoplasm and 
nuclei are negative (haematoxylin). Arrows indicate nuclear 
staining. The scale bars are 50 (top figures) and 20 μm 
(bottom figures). (B): Optical Healthy normal-weight dogs 
present cells with a higher optical density (greater 
immunostaining) than dogs with HAC (**P<0.01). Values 
are expressed as mean ±SEM. 
 
Similar results were found in basic research. 11β-HSD1 
knock-out HAC model mice (in all tissues) were 
protected from the adverse effects of cortisol, with no 
hypertension, no muscle atrophy, no hepatic steatosis, 
and no increase in visceral fat (Morgan et al., 2014). 
Additionally, 11β-HSD1 knock-out mice (adipose) 
were protected against hepatic steatosis, lipolysis in 
their adipose tissues, and excess plasma free fatty acids 
but did not fail to present muscular and dermal atrophy, 
hypertension, and deposition of visceral fat (Morgan et 
al., 2014). These results suggest that the local 
metabolism of glucocorticoids mediated by the 11β-
HSD1 enzyme plays a decisive role in the development 
of the complications of hypercortisolism, thereby 
challenging the classical view that active 
glucocorticoids in circulation represent the most 
important mode of action of glucocorticoids (Morgan 
et al., 2016). Conversely, the local metabolism of 
glucocorticoids in visceral adipose tissue would play a 
central but by no means absolute role in the 
development of metabolic disturbances of 
hypercortisolism, especially hepatic and lipid 
alterations. In agreement with these results, HAC dogs 
in general and the dogs evaluated in this study in 
particular present clinical alterations typical of 
hypercortisolism. 
Interestingly, evaluation of 11β-HSD1 enzyme 
expression in the dogs by western blotting did not 
reveal the typical 34 kDa and 68 kDa bands found in 
humans due to the enzyme’s dimeric structure 
(Mariniello et al., 2006). Instead, we found a single 
band that was 50 kDa in size. Kannisto et al. (2004) also 
reported the existence of this band in human visceral 
adipose tissue. 
Few studies have evaluated 11β-HSD1 expression in 
humans with HAC. Mariniello et al. (2006) found no 
significant differences between 11β-HSD1 expression 
in visceral adipose tissue from humans with HAC and 
healthy normal-weight patients. These authors 
postulated that the lack of an increase in 11β-HSD1 
expression in patients with HAC could be due to down-
regulation of the enzyme as a result of chronic over-
stimulation of plasma glucocorticoids. 
Most studies in human medicine on obesity, metabolic 
syndrome, and 11β-HSD1 have argued that 11β-HSD1 
is overexpressed in adipose tissues in patients with 
central obesity compared to control patients (Paulmyer-
Lacroix et al., 2002; Mariniello et al., 2006; Espíndola-
Antunes and Kater 2007; Candia et al., 2012), with 
increased local production of glucocorticoids that 
amplifies the effects. Iwasaki et al. (2008) postulated 
that metabolic syndrome would favour an intracellular 
Cushing state caused by overexpression of the 11β-
HSD1 enzyme. 
For future research, it would be interesting to develop 
new therapies that act specifically on 11β-HSD1 and 
thus be able to control hypercortisolism. Likewise, it 
would be interesting to evaluate if the different 
therapies already known for HAC act on 11β-HSD1, 
since it has been described that trilostane could have an 
effect on it (Teshima et al., 2014). 
Adrenal steroidogenesis is mainly regulated by ACTH. 
However, numerous factors not related to ACTH play 
roles in the regulation of the hypothalamus-adrenal-
hypophysis axis (Bornstein et al., 2008). 
Neuropeptides, growth factors, cytokines, opioids, 
adipokines, bacterial ligands, and other locally 
produced molecules synergize or antagonize the action 
of ACTH (Bornstein et al., 2008; Hochol et al., 2004; 
Conconi et al., 2006). It is well known that NO 
regulates steroidogenesis in cells of the adrenal 
glomeruli zone (Natarajan et al., 2002), besides acting 
on granulosa-luteal cells of the human ovary (Van 
Voorhis et al., 1994) and on Leydig cells (Del Punta et 
al. 1996; Mondillo et al., 2009). Thus, it is postulated 
that dissociation between ACTH and the plasma 
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glucocorticoid levels would occur under certain 
circumstances, indicating that the adrenal glands would 
have some "autonomy" with respect to pituitary 
regulation (Bornstein et al., 2008). This dissociation 
would occur under both physiological (Choi et al., 
2007) and pathological conditions, including 
inflammatory processes, critical illnesses, and mental 
disorders (Vermes and Beishuizen, 2001; Carroll et al., 
2007). 
In the study on adrenal glands, we observed that the 
expression of the eNOS enzyme evaluated through 
immunohistochemistry was lower in the dogs with 
HAC than in the control dogs. The role of NOS in 
modulating the synthesis of cortisol in the adrenals has 
been documented and is known to be involved in the 
fine regulation (inhibitory) of steroidogenesis 
(Cymeryng et al., 1998, 2002; Repetto et al., 2010) as 
an intracellular autoregulatory mechanism. However, 
no studies have been performed in dogs with HAC for 
comparison with our observations. Our results support 
the hypothesis that the lower eNOS expression in the 
adrenal glands of HAC dogs could reduce the 
modulatory effect of NO on steroidogenesis, leading to 
insufficient inhibition of cortisol synthesis. On the 
other hand, it is well know that cortisol inhibits NOS 
leading to a decrease in NO circulating (Yang and 
Zhang, 2004; Liu et al., 2009; Cabrera Blatter et al., 
2012). Taking this mechanism into account, 
hypercortisolism could reduce the expression of 
adrenal eNOS, and therefore, its inhibitory mechanism 
of steroidogenesis would be reduced. 
NOS is an enzyme that has numerous cellular locations 
(cytosol, mitochondria, Golgi apparatus, and nucleus) 
that confer different functions (Oess et al., 2006). In 
contrast to the observations in the zona fasciculata of 
the adrenals of the control dogs, where immunostaining 
indicated strong eNOS expression in the cytoplasm and 
nucleus, cytoplasmic labelling and, to a lesser extent, 
nuclear staining was observed in the dogs with HAC. 
Taken together, these results not only suggest that 
eNOS is expressed at lower levels in the adrenals of 
dogs with HAC but also that the expression sites may 
be reduced. Cymeryng et al. (1998, 2002) showed that 
eNOS expression was increased in mouse 
adrenocortical tumours (Y1 line) relative to normal 
adrenals. Therefore, evaluating eNOS expression in 
dogs with adrenal tumours producing HAC and the 
expression of the different isoenzymes in other tissues 
from dogs with HAC will be interesting. 
In conclusion, expression of the 11β-HSD1 enzyme is 
increased in the visceral adipose tissues of dogs with 
HAC, which could favour a sustained increase in 
plasma cortisol in these patients. Similarly, the 
expression of the eNOS enzyme is decreased in the 
adrenal glands (zona fasciculata) of dogs with HAC, 
which could lead to a lack of inhibition of NO-mediated 
steroidogenesis. Both enzymatic alterations could 
intervene in the maintenance of hypercortisolism, 
thereby favouring the establishment and/or 
maintenance of the comorbidities associated with this 
disease. 
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